T
Tomek J. Guzik
Researcher at Jagiellonian University
Publications - 3
Citations - 1945
Tomek J. Guzik is an academic researcher from Jagiellonian University. The author has contributed to research in topics: Aspirin & Placebo. The author has an hindex of 3, co-authored 3 publications receiving 1407 citations. Previous affiliations of Tomek J. Guzik include University of Glasgow.
Papers
More filters
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelley R. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +50 more
TL;DR: In a large placebo-controlled randomized trial, it is found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections.
Journal ArticleDOI
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelly R.H. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +51 more
TL;DR: Routine use of proton pump inhibitors in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease does not reduce upper gastrointestinal events but may reduce bleeding from gastroduodenal lesions.